Mural Oncology (NASDAQ:MURA) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Mural Oncology (NASDAQ:MURA) in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has a $18.00 target price on the stock.

Separately, Raymond James assumed coverage on shares of Mural Oncology in a research report on Friday, October 4th. They set a “strong-buy” rating and a $18.00 price objective for the company.

Mural Oncology Price Performance

Mural Oncology stock opened at $3.49 on Monday. Mural Oncology has a 52 week low of $2.88 and a 52 week high of $17.00. The stock has a fifty day moving average of $3.38 and a 200-day moving average of $3.38.

Mural Oncology (NASDAQ:MURA) last issued its earnings results on Tuesday, August 13th. The company reported ($1.86) EPS for the quarter, topping the consensus estimate of ($1.90) by $0.04. On average, sell-side analysts anticipate that Mural Oncology will post -7.59 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Adam D. Cutler sold 7,421 shares of the stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $3.41, for a total value of $25,305.61. Following the completion of the sale, the chief financial officer now directly owns 71,438 shares in the company, valued at $243,603.58. This represents a 9.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On Mural Oncology

Institutional investors have recently made changes to their positions in the stock. Harbor Capital Advisors Inc. acquired a new position in shares of Mural Oncology in the second quarter worth approximately $115,000. Rhumbline Advisers acquired a new position in shares of Mural Oncology in the 2nd quarter worth approximately $34,000. BBR Partners LLC bought a new stake in shares of Mural Oncology in the 2nd quarter valued at $31,000. Acadian Asset Management LLC acquired a new stake in shares of Mural Oncology during the second quarter worth $998,000. Finally, Nicollet Investment Management Inc. bought a new position in Mural Oncology during the second quarter worth $308,000. Institutional investors own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.